Cat. No.: HY-141867

Z-FF-FMK

(Synonyms: Z-Phe-Phe-FMK)

Customer Review

Based on 1 Customer Validation

Z-FF-FMK (Z-Phe-Phe-FMK) is a cell-permeable, irreversible, and cysteine protease inhibitor targeting cathepsin-L. Z-FF-FMK inhibits angiotensin II-induced MEK activation in vascular walls, aortic medial remodeling, blood pressure elevation, and upregulation of cystatin C in aortic walls. Z-FF-FMK prevents β-amyloid-mediated caspase-3 activation, poly (ADP-ribose) polymerase cleavage, DNA fragmentation, and apoptosis of cortical neurons (apoptosis). Z-FF-FMK can be used in research related to hypertension and Alzheimer's disease.

For research use only. We do not sell to patients.

Purity: 95.98%
CAS No.: 105608-85-3
Formula: C₂₇H₂₇FN₂O₄
Molecular Weight:462.51

Storage:

Sealed storage, away from moisture.

Powder -80°C, 2 years , -20°C, 1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Z-FF-FMK Chemical Structure

CAS No.: 105608-85-3

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]^[2]

cathepsin L

Caspase 3

All Cathepsin Isoforms :

All MEK Isoforms :

All Caspase Isoforms :

All DNA/RNA Synthesis Isoforms :

In Vitro

Z-FF-FMK (10 μM; 6 h) potently inhibits basal and Aβ-stimulated cathepsin-L activity in primary cultured rat cortical neurones, reducing basal activity to near undetectable levels and eliminating the 6 h Aβ-induced activity increase^[2].
Z-FF-FMK (10 μM; 24 h) completely prevents Aβ_1-40-induced caspase-3 activation in primary cultured rat cortical neurones after 24 h of co-incubation^[2].
Z-FF-FMK (10 μM; 24 h) fully blocks Aβ_1-40-stimulated caspase-3 activity in primary cultured rat cortical neurones after 24 h of co-incubation^[2].
Z-FF-FMK (10 μM) completely inhibits Aβ_1-40-induced PARP cleavage in primary cultured rat cortical neurones^[2].
Z-FF-FMK (10 μM; 72 h) fully prevents Aβ_1-40-induced DNA fragmentation in primary cultured rat cortical neurones after 72 h of co-incubation^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Z-FF-FMK (10 mg/kg; i.p.; every other day; 28 days) significantly mitigates angiotensin II-induced hypertension, aortic media remodeling, MEK phosphorylation, cystatin C upregulation, and elevated cathepsin L activity in C57BL/6 mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6 wild-type (8-12 weeks old; angiotensin II-induced hypertension model)^[1]
Dosage:

10 mg/kg
Administration:

i.p.; every other day; 28 days
Result:

Almost completely blocked angiotensin II-induced aortic artery media remodeling, reducing media thickness from a 2.1-fold increase (vs. control) to a 1.3-fold increase (vs. control).
Prevented angiotensin II-induced systolic blood pressure elevation, maintaining systolic blood pressure near baseline (~100 mmHg) compared to the ~160 mmHg peak in angiotensin II-only mice.
Suppressed angiotensin II-induced increases in aortic p-MEK expression, reducing from a 3.2-fold increase vs. control to a 1.2-fold increase vs. control.
Suppressed angiotensin II-induced increases in cystatin C expression, reducing from a 0.8-fold increase vs. control to a 0.4-fold increase vs. control.
Normalized angiotensin II-induced elevated arterial cathepsin L activity to control levels.

Chemical Information

CAS No. 105608-85-3
Appearance Solid
Molecular Weight 462.51
Formula C₂₇H₂₇FN₂O₄
Color White to off-white
Synonyms

Z-Phe-Phe-FMK
Sequence

Z-Phe-Phe-FMK
Sequence Shortening

Z-FF-FMK
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (216.21 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1621 mL

10.8106 mL

21.6212 mL

5 mM

0.4324 mL

2.1621 mL

4.3242 mL

10 mM

0.2162 mL

1.0811 mL

2.1621 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (275 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Lu Y, et al. Angiotensin II-Induced vascular remodeling and hypertension involves cathepsin L/V-MEK/ERK mediated mechanism. International Journal of Cardiology. 2020 Jan 1;298:98-106.

[2]. Boland B, et al. Abeta-mediated activation of the apoptotic cascade in cultured cortical neurones: a role for cathepsin-L. Neurobiol Aging. 2004;25(1):83-91. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.1621 mL	10.8106 mL	21.6212 mL	54.0529 mL
	5 mM	0.4324 mL	2.1621 mL	4.3242 mL	10.8106 mL
	10 mM	0.2162 mL	1.0811 mL	2.1621 mL	5.4053 mL
	15 mM	0.1441 mL	0.7207 mL	1.4414 mL	3.6035 mL
	20 mM	0.1081 mL	0.5405 mL	1.0811 mL	2.7026 mL
	25 mM	0.0865 mL	0.4324 mL	0.8648 mL	2.1621 mL
	30 mM	0.0721 mL	0.3604 mL	0.7207 mL	1.8018 mL
	40 mM	0.0541 mL	0.2703 mL	0.5405 mL	1.3513 mL
	50 mM	0.0432 mL	0.2162 mL	0.4324 mL	1.0811 mL
	60 mM	0.0360 mL	0.1802 mL	0.3604 mL	0.9009 mL
	80 mM	0.0270 mL	0.1351 mL	0.2703 mL	0.6757 mL
	100 mM	0.0216 mL	0.1081 mL	0.2162 mL	0.5405 mL

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Z-FF-FMK

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Metabolism/Protease Compound Library

Anti-Aging Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Ferroptosis Compound Library

Pyroptosis Compound Library

Anti-Alzheimer's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Peptide Library

Pain-Related Compound Library

Protease Inhibitor Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Peptide Compound Library

Bioactive Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

All Cathepsin Isoforms

All MEK Isoforms

All Caspase Isoforms

All DNA/RNA Synthesis Isoforms

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Z-FF-FMK Related Classifications

HY-141867 Related Classifications